Non-localizing SPECT-CT performed within 365 days prior to consent to participate in study
Patient desires surgical intervention for treatment of PHPT
No contraindications to 99mTC-Sestamibi
No contraindications to treatment with calcitonin
Serum calcium level prior to non-localizing SPECT-CT is ≥10.5 mg/dL
Patient consents to participate and undergo second SPECT-CT for purposes of research
You may not be if
Previous surgery to the neck, including resection of parathyroid tissue, except where end organ damage is present and further surgical intervention is medically necessary
Contraindication to 99mTC-Sestamibi SPECT-CT as evidenced by allergic reaction or adverse event during index SPECT-CT
Allergy to calcitonin
Hypocalcemia (contraindication to calcitonin)
Vitamin D deficiency (contraindication to calcitonin)
Previous treatment with radioactive iodine
New prescription of thyroid medication (levothyroxine, armour thyroid tablets, etc. must be taken at time of index scan and research scan)
Lithium exposure within one year of SPECT-CT (index and research scans)
Secondary hyperparathyroidism
Benign familial hypocalciuric hypercalcemia
Known malignancy, particularly multiple endocrine neoplasia
New prescription of thiazide diuretic, (thiazide diuretic must have been taken at the time of index scan and second scan)
Currently taking calcium channel blockers
Pregnancy
Clareo Health | Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
